Coronavirus Update: As Pfizer/BioNTech Begin Omicron Vaccine Tests, Regulators Want To Explore Multivalent Route
Plus: One Step Forward For Veklury, Two Steps Back For REGEN-COV
Pfizer explores options for new vaccine update, Veklury expands to non-hospitalized patients but Regeneron and Lilly therapies stopped in face of Omicron efficacy drop-off.
You may also be interested in...
Coronavirus Update: FDA Tries To Control J&J’s Vaccine, Extended Use Of Paxlovid
The FDA has also moved to limit use of J&J’s COVID-19 vaccine amid reports of rare but dangerous blood clots, while Regeneron highlighted efforts to get approval for REGEN-COV in its Q1 earnings.
Moderna COVID-19 Vaccine Data Bring Multivalent Vs. Monovalent Debate Into Focus
Phase II/III data for mRNA-1273.211 showed superiority against variants of concern to the original Spikevax, but Moderna’s top competitor has questioned the need for multivalent approaches.
Eiger Has Positive Data For Its COVID-19 Drug, But Faces Uncertain Market
Peginterferon lambda helped reduce hospitalizations and deaths among high-risk COVID-19 patients in a Phase III trial.